2024-18267. Medical Devices; General Hospital and Personal Use Devices; Classification of the Intravenous Catheter Force-Activated Separation Device
Table 1—Intravenous Catheter Force-Activated Separation Device Risks and Mitigation Measures
Identified risks to health Mitigation measures Delays of therapy due to failure of device to function as expected ( e.g., if separation force too low) Performance data, Non-clinical performance testing, and Labeling. Mechanical complications ( e.g., IV dislodgement, IV infiltration, occlusion, and phlebitis events requiring IV replacement) due to failure of device to function as expected ( e.g., if separation force too high) Performance data, Non-clinical performance testing, and Labeling. Infection Sterilization validation, Shelf life testing, Non-clinical performance testing, and Labeling. Air embolism Non-clinical performance testing, and Labeling. ( print page 66560) Adverse tissue reaction Biocompatibility evaluation, Pyrogenicity testing, and Non-clinical performance testing.
Document Information
- Effective Date:
- 8/16/2024
- Published:
- 08/16/2024
- Department:
- Food and Drug Administration
- Entry Type:
- Rule
- Action:
- Final amendment; final order.
- Document Number:
- 2024-18267
- Dates:
- This order is effective August 16, 2024. The classification was applicable on May 27, 2021.
- Pages:
- 66558-66560 (3 pages)
- Docket Numbers:
- Docket No. FDA-2024-N-3356
- Topics:
- Medical devices
- PDF File:
- 2024-18267.pdf
- CFR: (1)
- 21 CFR 880